The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset

Acta Neuropathol. 2014 May;127(5):779-80. doi: 10.1007/s00401-014-1265-3. Epub 2014 Mar 11.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiparkinson Agents / pharmacology*
  • Benzodioxoles / pharmacology*
  • Body Weight
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Mice, Transgenic
  • Parkinsonian Disorders / drug therapy*
  • Parkinsonian Disorders / physiopathology
  • Pyrazoles / pharmacology*
  • Time Factors
  • alpha-Synuclein / genetics
  • alpha-Synuclein / metabolism

Substances

  • 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole
  • Antiparkinson Agents
  • Benzodioxoles
  • Pyrazoles
  • SNCA protein, human
  • alpha-Synuclein